To date, at least three clinical trials are dedicated to the development of HERV-Env based therapies for MS (2) and type I diabetes (1) (sources: clinicaltrials.gov, USA; clinicaltrialsregister.eu, EU). Here, ERVW-1 is linked to myeloid sarcoma.